Marta Kisiel | Occupational Health | Research Excellence Award

Published on by Health Scientists

Dr. Marta Kisiel | Occupational Health | Research Excellence Award 

Associate Professor | Uppsala University | Sweden

Marta A. Kisiel is a specialist physician and Associate Professor in Occupational and Environmental Medicine at Uppsala University and Uppsala University Hospital, with an interdisciplinary background spanning medicine, polymer chemistry, and environmental health sciences. Her academic profile is distinguished by a strong integration of clinical practice and translational research, with a primary focus on the health effects of environmental and occupational exposures, post-viral conditions, work capacity, quality of life, respiratory function, and biological markers of disease. She has led and contributed to major research initiatives on post-COVID conditions and socioeconomic inequalities in environmental health risks, supported by competitive national foundations and regional research councils. Her publication record reflects sustained productivity in high-quality peer-reviewed journals with consistent citation impact, demonstrating both scientific rigor and international visibility. Dr. Kisiel maintains active collaborations with multidisciplinary teams across Sweden and internationally, including partnerships in clinical medicine, public health, and preventive psychiatry, and she has been instrumental in establishing cross-specialty clinical forums that bridge pulmonology, dermatology, and occupational medicine. As a principal investigator and supervisor, she plays a central role in training doctoral candidates and mentoring early-career clinicians and researchers, while also contributing extensively to undergraduate and specialist medical education through course leadership, thesis supervision, and problem-based learning. Beyond academia, she serves as an expert advisor to regional health authorities on evidence-based care for post-COVID conditions, contributes to national clinical knowledge platforms, and regularly acts as peer reviewer and committee member within the scientific community. Through her combined research, teaching, clinical leadership, and policy advisory work, Dr. Kisiel has achieved significant societal impact by strengthening occupational health practice, informing public health decision-making, and advancing care for individuals affected by environmentally and work-related diseases.  She has 824 citations from 51 documents with an h-index of 16.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Thambamroong, T., Seetalarom, K., Saichaemchan, S., Pumsutas, Y., & colleagues. (2022). Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: A double-blind, placebo-controlled randomised phase IIa trial.

2. Chirapongsathorn, S., Rintaravitoon, W., Tangjaturonrasme, B., & colleagues. (2025). Effect of a ketogenic diet on metabolic dysfunction-associated steatotic liver disease (MASLD) progression: A randomized controlled trial.

3. Chirapongsathorn, S., Rintaravitoon, W., Tangjaturonrasme, B., & colleagues. (2023). Effect of a ketogenic diet on nonalcoholic fatty liver disease (NAFLD) progression: A randomized controlled trial.

4. Thambamroong, T., Seetalarom, K., Saichaemchan, S., Pumsutas, Y., & colleagues. (2022). Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: A double-blind, placebo-controlled randomised trial.

5. Satirapoj, B., Varothai, N., Boonyagarn, N., Pumsutas, Y., Chotsriluecha, S., & colleagues. (2020). Effect of renal specific oral nutrition (ONCE Renal) on dietary intake and serum electrolytes in chronic kidney disease stage IV.

Duo Liu | Epidemiology | Best Researcher Award

Published on by Health Scientists

Prof. Duo Liu | Epidemiology | Best Researcher Award 

Deputy Director, Department of Clinical Pharmacy | Harbin Medical University | China

Professor Duo Liu, Chief Pharmacist and Doctoral Supervisor at Harbin Medical University Cancer Hospital, is a distinguished pharmaceutical scientist whose research has significantly advanced the fields of pharmacogenomics, pharmacoepidemiology, and precision oncology. With a strong background in medical genetics and pharmacology, Professor Liu has developed a research portfolio that bridges molecular pharmacology with clinical translation, focusing on the genetic mechanisms underlying cancer susceptibility, therapeutic response, and drug resistance. His pioneering contributions include transcriptome-wide association studies identifying novel genetic determinants of pancreatic and prostate cancer risk, as well as investigations into the role of NADPH oxidase polymorphisms and oxidative stress in tumor biology and treatment outcomes. Professor Liu’s scholarly work, published in leading international journals such as Cancer Research, Carcinogenesis, and International Journal of Cancer, has garnered wide recognition for its methodological rigor and clinical relevance. He has successfully led multiple national and institutional research grants, including projects supported by the National Natural Science Foundation of China, and has been honored with several prestigious distinctions for excellence in pharmaceutical sciences and young investigator achievements. As an active member of numerous professional societies, including the Chinese Pharmacological Society and the Anti-Cancer Association of China, Professor Liu contributes to shaping the evolving landscape of cancer pharmacotherapy and drug epidemiology. His collaborations with global research institutions, notably the University of Hawaii Cancer Center, underscore his commitment to advancing international scientific exchange and translational medicine. Through his leadership in clinical pharmacy and mentorship of emerging scientists, Professor Liu continues to drive innovation in personalized cancer treatment and rational drug use, promoting evidence-based healthcare practices that enhance patient outcomes and public health impact worldwide.

Profile: ORCID 

Featured Publications

1. Chen, C., Dong, Q., Wang, H., Dong, S., Wang, S., Lin, W., Jia, C., Dong, M., Jin, Y., & Liu, D. (2025, January 8). The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients. Annals of Hematology.

2. Wang, S. F., Dong, S. Q., Dong, Q., Lin, W. X., Dong, M., & Liu, D. (2024). Natural product-induced oxidative stress-synergistic anti-tumor effects of chemotherapeutic agents. Traditional Medicine Research.

3. Dong, S., Chen, C., Di, C., Wang, S., Dong, Q., Lin, W., & Liu, D. (2024, December). The association between NADPH oxidase 2 (NOX2) and drug resistance in cancer. Current Cancer Drug Targets.

4. Liu, D., Bae, Y. E., Zhu, J., Zhang, Z., Sun, Y., Deng, Y., Wu, C., & Wu, L. (2023, December 15). Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk. Carcinogenesis.

5. Liu, D., Zhao, T., Zhu, J., Sharapov, S., Tiys, E., & Wu, L. (2023, December 4). Associations between genetically predicted plasma N-glycans and pancreatic cancer risk. All Life.